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Background: Idiopathic pulmonary fibrosis (IPF) is an adult-onset Idiopathic Interstitial Pneumonia (IIP) usually
diagnosed between age 50 to 70 years. Individuals with Familial Pulmonary Fibrosis (FPF) have at least one affected
first or second-degree relative and account for 0.5-20% of cases.
Methods: We ascertained and collected DNA samples from a large population-based cohort of IPF patients from
Newfoundland, Canada. For each proband, a family history was documented and medical records were reviewed.
Each proband was classified as familial (28 patients) or sporadic (50 patients) and all 78 probands were screened for
variants in four highly penetrant, adult-onset PF genes (SFTPC, SFTPA2, TERT, TERC).
Results: Seventy-eight IPF probands were enrolled of whom 28 (35.9%) had a positive family history. These 28
familial patients led to the recruitment of an additional 49 affected relatives (total of 77 FPF patients). By age
60 years, 42% of the familial cohort had been diagnosed with PF compared with only 16% of the sporadic patient
collection (χ2 = 8.77, p = 0.003). Mean age of diagnosis in the familial group was significantly younger than the
sporadic group (61.4 years vs. 66.6 yrs, p = 0.012) with a wider age range of diagnosis (19–92 years compared with
47–82 years). Thirty-three of 77 (42.8%) FPF patients had a tissue diagnosis and all but five had usual interstitial
pneumonia histology. Compared with other published case series, the familial IIP histologies were more
homogeneous. Three of 28 familial probands (10.7%) and none of the 50 sporadic probands had pathogenic
variants in the four genes tested. All three familial probands had mutations in TERT. Other phenotypes associated
with telomerase deficiency were present in these families including cirrhosis, bone marrow hypoplasia and
premature graying. Telomere length assays were performed on mutation carriers from two families and confirmed
telomere-related deficiency.
Conclusion: The proportion of familial cases in our cohort is higher than any previously reported estimate and we
suggest that this is due to the fact that Newfoundland cohort is ethnically homogeneous and drawn from a
founder population. In our patient collection, diagnosis with IPF prior to age 45 years predicted familial disease. In
two of the three TERT mutation families, the pedigree appearance is consistent with genetic anticipation. In the
other 25 FPF families negative for mutations in known PF genes, we did not identify other telomerase associated
medical problems (bone marrow dysfunction, cirrhosis) and we hypothesize that there are novel PF genes
segregating in our population.
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Idiopathic Pulmonary Fibrosis (IPF) is an adult-onset lung
disease, which is a subtype of Idiopathic Interstitial Pneu-
monia (IIP). It is usually diagnosed between age 50 and
70 years and its histologic correlate is Usual Interstitial
Pneumonitis (UIP). The only treatment that improves
survival is lung transplantation. Without treatment, mean
survival ranges from 2 to 4 years [1-3]. The prevalence of
IPF in the United States is 14 per 100,000 [4].
Sporadic and familial forms of IPF have been recog-
nized [5-7]. Risk factors for sporadic disease include
male sex, cigarette smoking, metal and wood dust ex-
posure and exposure to particular medications, including
methotrexate and bleomycin [2,7].
Reports of familial forms of this disease (familial pul-
monary fibrosis or FPF) date back to 1958 [8] and
Online Mendelian Inheritance in Man lists FPF as an
autosomal dominant disorder with variable penetrance
(OMIM# 178500). Using a survey of respirologists in
the United Kingdom, Marshall and colleagues [6] esti-
mated the prevalence of FPF as 0.5-2.2% of all IPF
cases. Using a similar survey of Finnish pulmonary
clinics, 3.3-3.7% of Finnish cases were familial [9]; how-
ever, these studies may have underestimated the true
proportion of PF patients who have an affected first- or
second-degree relative. For example, 9/47 (19.1%) PF
patients who received a lung transplant through the
Vanderbilt lung transplant service reported a relative
with Interstitial Lung Disease (ILD) [10] and in a review
of the genetics of PF, these authors indicated that, in
their experience, 20% of PF is familial [11]. In a
Netherlands IPF cohort of 118 unrelated patients, 19.5%
were classified as having FPF with 2 or more affected
first-degree relatives [12].
Several publications have compared the clinical fea-
tures of familial and sporadic PF patients, and there
were no distinguishing features apart from a younger
mean age at diagnosis (ranging from 3.5 to 12 years) in
the familial compared with the sporadic groups
[6,7,9,12,13].
Eight to 18% of FPF patients have autosomal dominant
mutations in one of the two genes encoding the essential
components of telomerase: TERT (telomerase reverse
transcriptase) and TERC (telomerase RNA component)
[14]. Telomerase maintains the integrity of the ends of
chromosomes and all mutation-positive individuals have
telomere shortening of circulating lymphocytes [15-17].
Alder et al. [18] screened 100 sporadic PF patients and
found that 10% had telomere lengths < 1st percentile for
age, and Cronkhite et al. [17] found that telomere length
was less than the 10th percentile in 23% of sporadic and
24% of familial PF cases. This suggests that in at least
one-quarter of PF patients, perturbations in telomere
maintenance are involved in disease pathogenesis.Autosomal dominant mutations in surfactant protein
C (SFTPC) and in surfactant protein A2 (SFTPA2) have
also been indentified in familial IIP patients, but these
genes appear to be infrequently mutated in familial and
sporadic cohorts [19-21], with the exception of the
Dutch cohort reported in 2010 [12].
In this study we have addressed the following research
questions: (1) What is the prevalence of pulmonary fi-
brosis in Newfoundland? (2) Are there significant clinical
differences between sporadic and familial PF?, and (3)
What is the contribution of the known, highly penetrant
pulmonary fibrosis causing genes in this population?
Methods
Proband and family recruitment
From January 2006 to July 2011, we attempted to ascer-
tain all prevalent cases of IPF/FPF in the Canadian prov-
ince of Newfoundland and Labrador (NL), which has a
population of 509,000 [22]. The province’s five respirolo-
gists referred any patient with a diagnosis of IPF to the
study. Ninety percent of probands agreed to participate.
For each consenting patient, medical records were
reviewed. Probands either had biopsy proven UIP on a
clinical pathology report or, in the absence of surgical
lung biopsy, met the ATS/ERS (American Thoracic
Society/European Respiratory Society) criteria for IPF
[3], with the caveat that abnormal pulmonary function
testing was required show evidence of restriction and/or
impaired gas exchange. Memorial University’s Human
Investigations Committee approved this study (#02.26)
and all individuals consented to be in the study.
Each eligible proband completed a family history form,
a medical history form and a questionnaire that included
questions about tobacco use, occupation, and exposure
to fibrogenic dusts and drugs. Patients with significant
environmental exposures known to be associated with
lung fibrosis, or with known collagen vascular diseases,
were excluded from the study.
Using the family history, each proband was classified
as sporadic, familial or equivocal. Sporadic probands had
no family history of PF on a three-generation pedigree.
A familial proband was defined as an individual with PF
who had at least one affected first- or second-degree
relative (with the diagnosis of PF in the relative con-
firmed by medical record review). Relatives of familial
UIP probands who had other IIP histologies were also
asked to participate. Within each family, we attempted
to recruit all adult first-degree relatives of each affected
family member. Relatives were made aware of the possi-
bility of a subclinical diagnosis and those who consented
completed the enrolment protocol including Pulmonary
Function Tests (PFTs) and a high-resolution chest CT
scan (HRCT). Probands with family histories suggestive
of inherited lung disease, but whose affected relatives
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sible), were classified as having equivocal family histories.
Radiologic, pathologic and clinical phenotyping
Two radiologists (RB, ES) independently reviewed the
chest radiographs and HRCT scans of all participants
(probands and relatives). Each HRCT was scored at five
levels using the Royal Brompton Hospital system [23]
and was classified into one of four categories: “definitely
affected with IPF”, “probably affected”, “possibly affected”
(early disease), and “unaffected”.
All pathology specimens (surgical lung biopsies and aut-
opsied lungs) were reviewed by one of two pathologists
(ND, DF). The specimens were classified as normal or ab-
normal. If abnormal, the histologic pattern was described.
The radiologists and pathologists were blinded to each
participant’s clinical status.
A clinical panel (BAF, GF, BN) reviewed each partici-
pant’s clinical history, PFTs and radiology (+/− path-
ology) designation. The panel gave each participant a
final classification of “definitely affected” with IPF (tissue
diagnosis of UIP and for familial cases, other IIP histo-
logy patterns were also accepted), “probably affected” (no
surgical biopsy or autopsy, but characteristic HRCTs and
PFTs with evidence of impaired gas exchange and/or
restriction), “possibly affected” (PFTs or HRCTs abnormal
and consistent with early ILD), or “unaffected”.
Analysis of clinical data
Only participants classified as “definitely” or “probably
affected” with IPF by the clinical panel were included in
the following analyses. Clinical and physiologic data
from the FPF group (77 patients) and the sporadic PF
group (50 patients) were analyzed using descriptive
statistics. The familial and sporadic groups were com-
pared using standard statistical approaches (χ2 test,
Student t-test with two-tailed distribution). For some
analyses, the group of affected individuals with FPF
was limited to those who were diagnosed because they
developed respiratory complaints (57 patients), exclud-
ing (because of lead-time bias) those who were diag-
nosed through this study by clinical screening.
DNA sequencing of candidate genes
Four of the known genes causing familial pulmonary fi-
brosis were sequenced in 28 FPF probands and 50 spor-
adic PF patients: TERT, TERC, SFTPC and SFTPA2.
DNA was extracted from whole blood using either a
simple salting out method [24] or by using the Wizard
Genomic DNA Purification Kit (Promega Corporation,
Madison, WI). DNA sequencing in both directions was
performed for all exons and exon/intron boundaries. Pri-
mers and PCR conditions are available upon request.
Primers were designed using the Primer3 v0.4.0 softwareapplication (http://frodo.wi.mit.edu/primer3/). Variant nomen-
clature and primers were derived from the following RefSeq
accession numbers: NG_009265.1 (TERT), NG_016363.1
(TERC), NG_016968.1 (SFTPC) and NG_013046.1 (SFTPA2).
Automated sequencing was performed on either an ABI
3130 Genetic Analyzer or an ABI 3730 Genetic Analyzer
(Applied Biosystems, Foster City, CA).
Analyses of telomere length
Five living mutation carriers from two of the three fam-
ilies with TERT mutations (R0851, R0892) had assays to
determine telomere length in lymphocytes. Unfortu-
nately, the only affected individual in family R1254 died
before we could draw blood for the telomere assay. The
procedure was performed by Repeat Diagnostics (Suite
209–267 West Esplanade, North Vancouver, BC,
V7M1A5, Canada) to measure the length of telomeres in
blood samples. Telomere lengths were then plotted on
graphs indicating Caucasian population averages for
telomere lengths in lymphocytes [25].
Results
Clinical data: Seventy-eight unrelated IPF patients were
enrolled, of whom 28 (35.9%) had a positive family his-
tory which was confirmed by record review and, where
possible, by clinical assessment of the affected relatives.
These 28 FPF probands led to the identification of an
additional 49 relatives with PF. The largest families each
contain eight affected individuals. With the exception of
three families (R0851, R0892, R1254), all family histories
were negative for other medical problems associated
with telomerase mutations (e.g. unexplained bone mar-
row failure, cryptogenic cirrhosis) and there were no
affected individuals with infantile or childhood onset
ILD. The total FPF (n = 77) and sporadic groups (n = 50)
were both slightly enriched for males (55.8% and 62%,
respectively).
The R0896 family was initially ascertained as two sep-
arate families that were later genealogically linked. Also,
six sporadic patients were reclassified as familial when
another affected relative was referred to the study.
This IPF cohort is entirely Caucasian, predominantly of
Irish/English ethnicity. Twenty-seven of the 28 familial
probands and 47 of 50 sporadic patients described them-
selves as “Newfoundlanders” with Irish and/or English
ancestors who have lived in the province for at least three
generations. One familial proband was from Nova Scotia
Canada (Scottish ethnicity). Two sporadic patients had
parents who were born in the United Kingdom (English
ancestory) and one of the parents of a third sporadic pa-
tient was born in Great Britain (English ancestory); his
other parent was from Newfoundland.
As of July 30, 2011, the dataset contained 34 living
familial and 19 living sporadic patients. Using an at risk
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the minimum prevalence of PF in Newfoundland is
13.22 per 100,000.
Fifty-seven of 77 (74.0%) FPF patients were diag-
nosed prior to enrolment in this study because they
presented to physicians with respiratory symptoms
(FPF-diagnosed clinically or FPF-DC). The remaining
20 FPF cases were diagnosed through this study by
family screening (FPF-diagnosed screening or FPF-DS)
(Table 1). The mean age of diagnosis was significantly
different between the clinically diagnosed FPF group
and the sporadic cohort (n = 50) (61.4 years versus
66.6 years, p =0.012). Forty-two percent of the FPF patients
who presented clinically were diagnosed by age 60 years,Table 1 Comparison of demographic and clinical variables be
Variables Total FPF
patients (N= 77)
FPF-D
(N= 5
Mean age symptom onset 57.11 57.97
(years)
Mean age at diagnosis (years) 60.65 61.43
Mean age at death or N/C 64.58
transplant (n = number of
deceased or transplanted patients)
Gender
Number (%) males M= 43 (55.8 %) M= 34
Number (%) females F = 34 (44.2 %) F = 23
Current or ever smokers (%) 61/76 (80.3 %) 45/56
Number of patients with symptom at diagnosis:
Dyspnea N/C 43 (75
Cough 37 (64
Chest pain 14 (24
Pneumonia 10 (17
Hemoptysis 5 (8.8
Pneumothorax 2 (3.5
Most specific diagnostic test:
Number of patients (%)
CXR 4 (5.2 %) 4 (7.0
HRCT 40 (51.9 %) 23 (40
Surgical lung biopsy 30 (39.0 %) 28 (49
Autopsy 3 (3.9 %) 2 (3.5
Treatments: Number of patients (%)
Prednisone 40 (51.9 %) 38 (66
Cyclophosphamide 7 (9.1 %) 7 (12.3
Azathioprine 12 (15.6 %) 11 (19
N-acetyl cysteine 16 (20.8 %) 13 (22
Lung transplant 5 (6.5 %) 5 (8.8
FPF = familial pulmonary fibrosis, FPF-DC = familial pulmonary fibrosis diagnosed be
pulmonary fibrosis diagnosed because the individual had clinical screening based o
CXR = chest X-ray, HRCT = high resolution computerized tomography of chest.whereas only 16% of the sporadic patients were diagnosed
by this age (χ2 =8.77; p=0.003). The cumulative risk of
lung transplant and/or death was compared for the
clinically diagnosed FPF patients and the sporadic patients.
By age 60 years, 19% of the clinically diagnosed FPF
patients were dead or had received a lung transplant com-
pared with 2% of the sporadic group. However the mean
age to death or transplant between the two groups was not
statistically significant (FPF 68.9 years and sporadic
73.7 years; p= 0.466).
Comparing the clinically diagnosed FPF and sporadic
groups, there was no statistically significant difference in
presenting symptoms or treatments. The commonest
presenting symptom was dyspnea and the mosttween familial and sporadic PF patients
C
7)
FPF-DS
(N =20)
Sporadic patients
(N= 50)
Significance of
difference
N/A 63.85 p=0.012
(FPF-DC vs. sporadic)
58.45 66.58 p=0.012
(FPF-DC vs. sporadic)
(n = 36) 73.62 (n = 6) 70.60 (n = 32) p=0.025
(FPF-DC vs. sporadic)
(59.6 %) M= 9 (45.0 %) M= 31 (62.0 %) p = 0.531
(40.4 %) F = 11 (55.0 %) F = 19 (38.0 %) (total FPF vs. sporadic)
(80.4 %) 16/20 (80.0 %) 42/50 (84.0 %) p = 0.767
(total FPF vs. sporadic)
FPF-DC vs. sporadic
.4 %) N/C 44 (88.0 %) p = 0.096
.9 %) 35 (70.0 %) p = 0.576
.6 %) 12 (24.0 %) p = 0.946
.5 %) 7 (14.0 %) p = 0.617
%) 1 (2.0 %) p = 0.129
%) 0 (0.0 %) p = 0.181
%) 0 (0.0 %) 0 (0.0 %)
.4 %) 17 (85.0 %) 31 (62.0 %)
.1 %) 2 (10.0 %) 21 (42.0 %)
%) 1 (5.0 %) 0 (0.0 %)
FPF-DC vs. sporadic
.7 %) 2 (10.0 %) 36 (72.0 %) p = 0.551
%) 0 (0.0 %) 2 (4.0 %) p = 0.170
.3 %) 1 (5.0 %) 12 (24.0 %) p = 0.555
.8 %) 3 (15.0 %) 20 (40.0 %) p = 0.055
%) 0 (0.0 %) 3 (6.0 %) p = 0.586
cause individual developed clinical symptoms of lung disease, FPF-DS = familial
n family history, N/A = not applicable, N/C = not calculated, %=percentage,
Table 3 Variants identified that are predicted to be
deleterious
Causative variant Predicted protein change Identified families
TERT: c.2648 T >G p.Phe883Cys R0892
TERT: c.1892 G>A p.Arg631Gln R0851
TERT: c.2594 G>A p.Arg865His R1254
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proportion of current or ever-smokers was similar be-
tween the two groups (FPF-diagnosed clinically 80.4%,
sporadic PF 84.0%).
Thirty-three FPF patients had either a surgical lung bi-
opsy or an autopsy, and of these 82% had UIP histology;
only 5 family members had pathology classified as an-
other form of IIP (Table 2). Twenty-one of the 50 (42%)
sporadic patients enrolled had clinical pathology reports
consistent with UIP. Following review by the research
pathologist, four of these were reclassified as having an-
other IIP histology and these cases were included in the
subsequent analyses.
The most consistently abnormal parameter on pul-
monary function tests (PFTs; Table 2), obtained at the
time of diagnosis, was the Diffusing Capacity of the Lung
for Carbon Monoxide (DLCO). It was below 80% of pre-
dicted in 97.5% and 88% of the FPF-diagnosed clinically
and sporadic cases, respectively (respective mean DLCOs
were 56.4% and 57.2% of predicted). Initial PFTs showed
an isolated reduction of DLCO in 33.3% and 35.9% in
each of these respective groups. Because of our enroll-
ment criteria, only about half of patients in each group
showed initial evidence of restriction on PFTs.
Sequencing of known PF-causing genes
Four genes previously known to cause hereditary pul-
monary fibrosis (TERT, TERC, SFTPC and SFTPA2) were
screened in our sporadic and familial cohorts, and the
only mutations found were in TERT in three unrelated
familial cases (Table 3). Hence we identified pathogenic
variants in three of 28 familial probands (10.7%) and
none of 50 sporadic probands. In family R0892, we iden-
tified a novel heterozygous TERT variant [c.2648 T>G
(p.Phe883Cys)] which was found in all affected family
members tested (n = 5) and is predicted to be “dam-
aging” using SIFT and “probably damaging” using Poly-
Phen (Additional file 1: Table S1). In family R0851, weTable 2 Comparison of pulmonary function tests (PFTs) at dia
diagnosed through screening (FPF-DS) and sporadic groups
PFT parameter Number (%) of
FPF-DC patients
with abnormal
findinga
Mean % of
predicted
value +/− SD
Numb
FPF-D
with
findin
FVC 23/45 (51.1 %) 78.4 % +/− 15.4 % 6/16 (
TLC 20/41 (48.7 %) 78.5 % +/− 15.4 % 6/16 (
FEV1 22/42 (52.3 %) 79.1 % +/− 15.1 % 5/16 (
DLCO 39/40 (97.5 %) 56.4 % +/− 15.7 % 12/16
Isolated reduction in
DLCO (other PFTs normal)
12/36 (33.3 %) N/C 6/16 (
SD= standard deviation, FVC = forced vital capacity, TLC = total lung capacity, FEV1 =
of the lung for carbon monoxide.
a Abnormal if: FVC, TLC, FEV1 or DLCO< 80 % predicted.identified a novel putatively pathogenic TERT variant
[c.1892 G>A (p.Arg631Gln)] that segregates in all
affected members of the nuclear family (n = 4). When
analyzed with bioinformatic programs, this variant was
deemed “damaging” by SIFT, and “possibly damaging” by
Polyphen. In family R1254, a heterozygous TERT muta-
tion [c.2594 G>A (p.Arg865His)] was identified in the
proband and his unaffected daughter (age 35). This vari-
ant has been previously published and proven to be
pathogenic [15]. Numerous other variants were identi-
fied which we considered neutral (benign) or of un-
known significance (Additional file 1: Table S1).
Telomere length assays
Telomere length assays carried out on five affected indi-
viduals with TERT mutations from two families (R0892
and R0851). All five patients had markedly short telo-
meres (≤10% ile of normal) when compared to Caucasian
population age-matched averages (Figure 1), supporting
the pathogenicity of the TERT variants identified in these
two families.
Discussion
Using a population based approach, we determined that
the minimum prevalence of PF in NL is 13.2 per
100,000, comparable to the prevalence of 14–20 per
100,000 from more admixed populations [4,26]. How-
ever, the proportion of familial cases (approximately
36%) is higher than previously reported estimates thatgnosis between clinically diagnosed FPF (FPF-DC), FPF
er (%) of
S patients
abnormal
ga
Mean % of
predicted
value +/− SD
Number (%)
of sporadic
PF patients
with abnormal
findinga
Mean % of
predicted
value +/− SD
37.5 %) 92.7 % +/−16.8 % 24/46 (52.2 %) 80.1 % +/− 19.3 %
37.5 %) 86.6 +/−19.6 % 19/41 (46.3 %) 80.2 % +/− 17.9 %
31.2 %) 87.1 % +/−12.9 21/46 (45.6 %) 81.5 % +/− 17.6 %
(75.0 %) 66.4 % +/−18.4 37/42 (88.0 %) 57.2 % +/− 23.2 %
37.5 %) N/C 14/39 (35.9 %) N/C
forced expiratory volume exhaled in the 1st second, DLCO = diffusing capacity
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partly due to ascertainment bias (respirologists being
more likely to refer familial than sporadic cases), the
province has a relatively small number of respirologists
and we were able to regularly communicate with them
to ensure more complete recruitment of patients regard-
less of family history. Hence the Newfoundland founder
population may be enriched for familial forms of PF.
This Canadian island is composed of a series of genetic
isolates and founder mutations have been demonstrated
for several autosomal dominant disorders including
arrhythmogenic right ventricular dysplasia type 5, Lynch
syndrome and hereditary diffuse gastric cancer syn-
drome [27-29]. This coupled with large family sizes has
led to increased prevalence of these genetic diseases
in NL.
van Moorsel et al. (2002) [12] reported the next high-
est proportion of familial cases in a UIP cohort, 23 of
118 IPF probands or 20%. The patients were ascertained
from a single Dutch ILD clinic, and although ethnicities
were not specified, the Netherlands has a relativelyA-2
A-1
B-2B-1
C) R1254
A) R0892
B) R0851
B-2
L
Deceased f
Mutation po+
Affected ma
Proband
dx 57y
dx 26y dx 28y dx 19y
dx 76y
dx 54y
dx 72ydx 65ydx 75y
dx 48y dx 56y
dx 42y
Figure 1 Pedigrees of families with TERT mutations. Mutation positive i
of pulmonary fibrosis. A) Novel TERT variant: c.2648 T >G (p.Phe883Cys) seg
(p.Arg631Gln) segregates with disease. C) Previously reported pathogenic T
and unaffected daughter. ILD= Interstitial lung disease. Telomere assays wehomogeneous population [30]. Five of 20 Dutch IPF
families segregated an SFTPC mutation [12], whereas no
pathogenic variants in SFTPC were found in 73
Newfoundland probands. Although the five Dutch
SFTPC cases had UIP histology, their HRCT scans were
not typical of IPF, with features that included diffuse
lung involvement, extensive ground glass and multiple
cysts In contrast, our 28 familial probands, who all
screened negative for SFTPC mutations, had HRCT
scans which were classified by our blinded radiology
panel as “definitely” or “probably” affected with IPF. The
lower proportion of familial disease reported by other
groups [6,9] is almost certainly due, at least in part, to
the limitations of identifying familial cases by mailing
questionnaires to patients and health care providers.
Consistent with previously published work [6,7,9,12],
we found that individuals with familial disease had a
younger mean age of diagnosis with no other clinically
distinguishing features (Table 4). Mean diagnosis age in
the Newfoundland FPF cohort (excluding relatives who
were diagnosed through clinical screening) was only fiveA-3
A-3
A-2
A-1
B-1
EGEND
emale
sitive
le
dx 72y
ndividuals are indicated by a “+” sign. Dx =Age at diagnosis
regates with the disease. B) Novel TERT variant: c.1892 G>A
ERT mutation: c.2594 G>A (p.Arg865His) present in affected patient
re not performed in this family.
Table 4 Idiopathic interstitial pneumonia (IIP) histologies
among FPF and sporadic PF patients with a tissue
confirmed diagnosis (surgical lung biopsy or autopsied
lungs)
All FPF
patients
(n = 77)
Sporadic PF
patients
(n = 50)
Number of patients with a tissue diagnosis (%) 33 (42.9 %) 21 (51 %)
Number of patients with IPF/UIP histology (%) 27 (81.8 %) 16 (76.2 %)
Number of patients with mixed UIP and NSIP
histology patterns (%)
1a 1
Number with IIP other than UIP (%): 3 2
NSIP 0 0
COP 0 0
AIP 0 0
RB-ILD 0 0
DIP 0 0
LIP Unclassifiable interstitial pneumonia 2 a 2
Total non-UIP histologic pattern 6 (18.2 %) 4 (19 %)
NSIP = non-specific interstitial pneumonia, COP= cryptogenic organizing
pneumonia, AIP = acute interstitial pneumonia, RB-ILD = respiratory
bronchiolitis-associated interstitial lung disease, DIP = desquamative interstitial
pneumomia, LIP = lymphocytic interstitial pneumonia.
a One biopsy showing a mix of UIP and NSIP and one biopsy showing
unclassifiable interstitial pneumonia come from 2 members of the same family
(R0892). The other 4 non-UIP biopsies from PF patients come from four
different families.
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group had a wider range of age at diagnosis (19–92 years
compared with 47–82 years in the sporadic group). Fif-
teen percent of the Newfoundland FPF cohort was diag-
nosed by 40 years; no sporadic case was diagnosed
before age 47. Hence in our patient collection the diag-
nosis of PF below age 45 predicted familial disease.
Interestingly, in the only penetrance study reported to
date, investigators reviewed 134 patients with TERT
mutations. PF never occurred before age 40, and devel-
oped in 60% of male mutation carriers by age 60 [31].Table 5 Comparison of pulmonary function tests (PFTs) obtai
diagnosed FPF (FPF-DC), FPF diagnosed through screening (F
PFT parameter Number (%) of
FPF-DC patients
with abnormal
findinga
Mean % of
predicted
value +/− SD
Numbe
FPF-DS
with ab
finding
FVC 32/44 (72.7 %) 70.5 % +/−19.5 % 6/16 (37
TLC 20/29 (69.0 %) 69.9 % +/− 17.0 % 5/15 (33
FEV1 35/43 (81.3 %) 68.6 % +/− 18.6 % 7/16 (43
DLCO 34/35 (97.1 %) 47.6 % +/− 20.1 % 15/16 (9
Isolated reduction in
DLCO (other PFTs normal)
4/25 (16.0 %) N/C 6/15 (40
SD= standard deviation, FVC = forced vital capacity, TLC = total lung capacity, FEV1 =
of the lung for carbon monoxide.
a Abnormal if: FVC, TLC, FEV1 or DLCO< 80 % predicted.In our IPF patient collection of 127 individuals, 54
patients (43%) had biopsy proven IIP, 81% of which was
UIP (Table 2). Those who did not have a biopsy were clas-
sified as having “probable IPF” if the HRCT showed typical
bibasilar abnormalities and if PFTs showed evidence of re-
striction or impaired gas exchange or both. The majority
of patients in both groups had a low DLco at diagnosis
(97.5% and 88% in the familial and sporadic groups re-
spectively), but only half of the patients in each group
showed initial evidence of restriction. Table 5 summarizes
the most recent follow-up PFT data from the FPF and
sporadic patients, showing that over time the proportion
of patients with restriction rose to 69%and 62.5% in the
clinically diagnosed FPF and sporadic groups.
Five earlier publications have described the clinical
features of familial IPF or IIP cohorts [6,7,9,12,32] and
in three of these comparisons were made to a sporadic
PF group collected by the authors [7,9,12]. In these five
studies, familial PF was defined as at least two cases of
PF within the same biologic family [6,7,9] or at least 2
cases in first-degree relatives [12,32].
In 2000, Marshal et al. [6] identified 21 IIP families
(containing 57 affected individuals) by mailing surveys
to adult respirologists in the United Kingdom. The co-
hort was probably ethnically heterogeneous and no at-
tempt was made to determine the patients’ IIP
classification. Mean age of diagnosis was younger than
in our familial cohort (55.5 years versus 61.4 years) and
the UK cohort had a lower proportion of current or ever
smokers (50% versus 80.3%).
In 2005 Lee et al. [7], published a well characterized
collection of 15 familial IPF families containing 47
affected individuals, with detailed clinical information
on 27 patents. This group represented all familial IPF
patients treated at the Mayo clinic in Minnesota over a
10-year period. The 27 familial cases were compared
to 63 sporadic IPF patients previously collected at their
institution. All available biopsies showed UIP. The mainned at most recent follow-up between clinically
PF-DS) and sporadic groups
r (%) of
patients
normal
a
Mean % of
predicted
value +/− SD
Number (%) of
sporadic PF
patients with
abnormal findinga
Mean % of
predicted
value +/− SD
.5 %) 90.3 % +/−17.8 % 33/47 (70.2 %) 69.9 % +/− 18.6 %
.3 %) 85.6 % +/−20.3 % 20/32 (62.5 %) 69.2 % +/− 17.2 %
.8 %) 83.2 % +/−15.6 % 32/47 (68.0 %) 71.8 % +/− 18.5 %
3.8 %) 60.2 % +/−13.8 % 35/38 (92.1 %) 47.3 % +/− 26.4 %
.0 %) N/C 2/29 (6.9 %) N/C
forced expiratory volume exhaled in the 1st second, DLCO = diffusing capacity
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http://respiratory-research.com/content/13/1/64familial versus sporadic comparisons were age at diagno-
sis (59.4 years versus 63 years), and median survival
which was similar between the 2 groups, at 2–3 years.
Steele et al. (2005) [32] recruited the largest familial
cohort to date, 111 families with IIP from three major U.
S. ILD treatment centers, containing 309 patients “defin-
itely” or “probably affected” with IIP. As observed in the
28 Newfoundland IPF families, the age range of diagno-
sis within American cohort was wide (30.3–95.4 years).
Fifty of the 111 families (45%) had radiology or
histopathology findings consistent with the presence of
more than one form of IIP within the family. In our fa-
milial group, only 18.2% of the patients had non-UIP
histology (Table 2). The unidentified PF genes segregat-
ing in the Newfoundland population may be associated
with a more homogenous phenotype than is typical of
the known PF causing genes. Alternatively, our recruit-
ment protocol may have biased against ascertainment of
families with multiple IIP histologies. While we accepted0964
1397
Figure 2 Map of Newfoundland showing geographic distribution of 2relatives with non-UIP histologies, all probands were
required to have a clinical diagnosis of IPF/UIP.
van Moorsel et al. (2010) [12] compared 22 unrelated
familial IPF patients from one Dutch centre to 95 spor-
adic IPF cases. Their familial group consisted of pro-
bands only, and their data confirmed that of the earlier
studies. No familial versus sporadic differences were
identified apart from younger diagnosis age in the famil-
ial group. Although not statistically significant, the
Newfoundland familial cohort was less enriched for
males than the sporadic patient collection (Table 4), and
this was also observed in van Moorsel’s study [12].
The only other published IPF cohort from a founder
population is Finnish. In comparison to the Newfound-
land founder families which are 10–20 generations old,
the Finnish population is older, dating back at least 100
generations [33]. Hodgson et al. [9] identified IPF
patients in Finland by reviewing hospital databases, and
familial cases were ascertained by mailing questionnaires0896, 
1211, 
2305, 
1224,
1947
0942,
0892
0851
2416
1136
1126
1275
1127
1254, 
1884
1351
2300
09822412
1460
1941
2306
1225
1462
8 families with familial pulmonary fibrosis.
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http://respiratory-research.com/content/13/1/64to living IPF patients with a response rate of 56%.
Detailed clinical parameters were not published, but the
only difference identified between the familial and spor-
adic groups was again mean age of diagnosis. The
seventeen multiplex PF families identified clustered in
eastern Finland [9]. The 28 Newfoundland families did not
come from a single region of the province (Figure 2), how-
ever all families except one originated from either the
eastern-most peninsula of the island or from the northeast
coast. Nevertheless, we found two distinct TERT mutations
in two families (R0851, R0892) from the island’s eastern-
most peninsula, indicating that neighbouring communities
may have independent mutations.
The identified autosomal dominant PF genes account
for no more than 15-20% of patients with familial dis-
ease [34,35], suggesting that there are unidentified PF
genes. Our molecular work supports this hypothesis.
Only three probands (all familial) from our total cohort
carried a pathogenic variant in a known PF-causing gene
(Figure 1). Family R0892 is segregating a TERT mutation
with five mutation-positive individuals who have devel-
oped PF, and six living affected individuals who are
mutation-positive without PF. There is also one
mutation-positive female who died at 88 years from con-
gestive heart failure, and at age 82, her HRCT scan and
PFTs were normal. Apart from premature graying (com-
pletely white hair by age 40) in one mutation-positive
person with PF, and in 5 mutation-positive individuals
without PF, no other telomerase associated medical pro-
blems were identified in this family. In R0892, the mean
age of diagnosis in the older generation was 72 years
compared with age 52.6 years in the younger generation,
consistent with the phenomenon of genetic anticipation
that has been reported in some families with telomerase
mutations ([reviewed in [36]). Individuals with TERT
mutations theoretically create gametes with relatively
short telomeres. If the conceptus is also mutation-posi-
tive, this short telomere length cannot be repaired
leading to even shorter telomere length for age than
was present in the mutation-positive parent. In the
second family with a TERT mutation (R0851), the
three affected brothers in the second generation had
other telomerase associated medical problems. All
three had bone marrow hypoplasia with chronically
low platelets and the older two developed cirrhosis of
unknown etiology. The eldest of the three had success-
ful liver and lung transplantations. The three brothers
were diagnosed with PF by the second decade of life
compared with their mother who was diagnosed at
42 years. In the third TERT mutation family (R1254),
the father of the proband died of cryptogenic cirrhosis.
The father’s chest X-rays showed mild changes consist-
ent with ILD, but no DNA was available to confirm
that he was mutation-positive.One limitation of our study is that we did not analyze
telomere lengths in the sporadic patients or in the 25 fa-
milial probands who did not have TERT mutations. Also
although we systematically assessed each participant for
liver disease and cytopenias, we did not collect data on
premature graying.
Conclusion
To date, autosomal dominant mutations in four genes
are known to cause adult onset IPF: SFTPC, SFTPA2,
TERC and TERT. We screened these genes in our famil-
ial (n = 28) and sporadic (n = 50) probands, 95% of whom
belong to the Newfoundland founder population. Except
for three familial patients with TERT mutations, no
causal variants were identified. We hypothesize that at
least one novel FPF gene is segregating in this popula-
tion. We are currently pursuing gene identification
through a combination of linkage analyses and exome
sequencing.
Additional file
Additional file 1: Table S1. List of variants in four FPF genes found in
affected family members and sporadic patients.
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